- Company
- 1st KRAS drug Lumakras can be prescribed at general hospital
- by Eo, Yun-Ho Sep 29, 2022 05:50am
- Lumakras, the first targeted anticancer therapy to target the KRAS mutation, can now be prescribed at general hospitals in Korea. According to industry sources, Lumakras (sotorasib), Amgen Korea’s treatment for locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations, passed the drug committees of the Big 5 tert
- Company
- Ildong applies to change trial protocol after completion
- by Kim, Jin-Gu Sep 29, 2022 05:50am
- Ildong Pharmaceutical and Shionogi Pharmaceutical submitted an application to modify their clinical trial protocol after completing the Phase 3 trial for their COVID-19 treatment. The industry saw this as Shionogi Pharmaceutical’s intent to reinterpret the clinical trial results around the Omicron variant. On the 27th, Ildong Pharmaceu
- Company
- FDA approved Celltrion's anticancer drug Avastin biosimilar
- by Chon, Seung-Hyun Sep 29, 2022 05:50am
- The 3.6 trillion won U.S. market has begun in earnest. Celltrion announced on the 27th that it has obtained a license from the Food and Drug Administration (FDA) to sell the Avastin biosimilar Vegzelma. Vegzelma has been approved for Avastin's indications, including metastatic direct bowel cancer, non-small cell lung cancer, metasta
- Company
- Daewoong Pharmaceutical SGLT-2 Diabetes New Envlo
- by Kim, Jin-Gu Sep 28, 2022 06:06am
- Daewoong Pharmaceutical has registered a trademark of Enavogliflozin, which is being developed as a new drug for treating diabetes in the line of SGLT-2 inhibitors. Daewoong Pharmaceutical temporarily confirmed the name of the single, second, and third complex series centered on Enavogliflozin as Envlo, and began the last-minute work with the
- Company
- 4th JAKi Cibinqo makes a step towards reimbursement
- by Eo, Yun-Ho Sep 28, 2022 06:06am
- The 4th JAK inhibitor, Cibinqo, is nearing insurance reimbursement in Korea. According to industry sources, Pfizer Korea’s new Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib)’ passed the review of the National Health Insurance Review and Assessment Service’s Drug Reimbursement Standard Subcommittee. The company applied for Cib
- Company
- MFDS allows academic marketing of EUA COVID-19 treatments
- by Sep 28, 2022 06:05am
- The Ministry of Food and Drug Safety gave an interpretation that allows academic marketing activities for oral COVID-19 treatments. As drugs approved under the Emergency Use Authorization are as validly approved as officially authorized drugs, such drugs that were left unattended by the Pharmaceutical Affairs Act can also be advertised with
- Company
- Reduce steroid in long-term use of Dupixent in asthmatic pts
- by Sep 28, 2022 06:05am
- Sanofi's Dupixent was found to improve major symptoms in a three-year long-term follow-up of severe asthma patients while reducing the use of oral corticosteroids. The results of these studies were released at the 2022 ERS Annual Academic Conference held from the 4th to the 6th. Through this conference, Dupixent released a number of data a
- Company
- MOHW's view of ‘few’ and ‘pediatric’ for PE exemptions
- by Eo, Yun-Ho Sep 27, 2022 05:51am
- Although yet to be finalized, the PE exemption criteria will not be amended' in the direction desired by pharmaceutical companies. In particular, companies are likely to have little room in utilizing the special exemption of the pharmacoeconomic evaluation system due to the restrictions set, such as treatments that are used by ‘few’ pat
- Company
- Daewoong Nabota is expected to take a global leap
- by Nho, Byung Chul Sep 27, 2022 05:51am
- As Daewoong Pharmaceutical's botulinum toxin product Nabota (Jubo·Jeubeau) is likely to surpass 100 billion won in sales this year, it is drawing attention as it is expanding its global scope as a representative K-toxin product. Nabota, which was launched in Korea in 2014, recorded 15.1 billion won in 2019 It achieved sales of 79.6 billio
- Company
- 4 pharmaceutical companies challenge to add Vemlidy patents
- by Kim, Jin-Gu Sep 27, 2022 05:51am
- Gilead Sciences' patent for hepatitis B treatment Vemlidy (Tenofovir) is increasing. While Dong-A ST, Daewoong Pharmaceutical, Chong Kun Dang, and Jeil succeeded in avoiding patents for the first time in March this year, Samjin, Hutechs, DongKook, and Samil have challenged the same patent for the past two months in a row. According to the pha
